|
US4444878A
(en)
|
1981-12-21 |
1984-04-24 |
Boston Biomedical Research Institute, Inc. |
Bispecific antibody determinants
|
|
US5156965A
(en)
|
1983-11-29 |
1992-10-20 |
Igen, Inc. |
Catalytic antibodies
|
|
US5229272A
(en)
|
1989-04-25 |
1993-07-20 |
Igen, Inc. |
Catalytic antibody components
|
|
US5030717A
(en)
|
1986-09-17 |
1991-07-09 |
Scripps Clinic And Research Foundation |
Antibodies which catalyze hydrolysis of ester bonds
|
|
US5126258A
(en)
|
1984-09-07 |
1992-06-30 |
Scripps Clinic And Research Foundation |
Molecules with antibody combining sites that exhibit catalytic properties
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
US4975278A
(en)
|
1988-02-26 |
1990-12-04 |
Bristol-Myers Company |
Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
|
|
US5851527A
(en)
|
1988-04-18 |
1998-12-22 |
Immunomedics, Inc. |
Method for antibody targeting of therapeutic agents
|
|
US5601819A
(en)
|
1988-08-11 |
1997-02-11 |
The General Hospital Corporation |
Bispecific antibodies for selective immune regulation and for selective immune cell binding
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US5858728A
(en)
|
1991-03-13 |
1999-01-12 |
Common Services Agency |
Monoclonal antibody against LPS core
|
|
ATE255131T1
(de)
|
1991-06-14 |
2003-12-15 |
Genentech Inc |
Humanisierter heregulin antikörper
|
|
AU6942394A
(en)
|
1993-04-23 |
1994-11-21 |
Igen, Inc. |
Catalytic antibodies which hydrolyze primary amides and methods for eliciting such antibodies
|
|
US5602021A
(en)
|
1994-12-29 |
1997-02-11 |
Catalytic Antibodies, Inc. |
Method for generating proteolytic enzymes specific against a selected peptide sequence
|
|
US5585108A
(en)
|
1994-12-30 |
1996-12-17 |
Nanosystems L.L.C. |
Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
|
JP2001501636A
(ja)
|
1996-10-04 |
2001-02-06 |
バイヤースドルフ・アクチエンゲゼルシヤフト |
化粧用もしくは皮膚科用のマイクロエマルションを基礎としたゲル
|
|
WO1998016254A1
(en)
|
1996-10-17 |
1998-04-23 |
Immunomedics, Inc. |
Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system
|
|
US6306393B1
(en)
|
1997-03-24 |
2001-10-23 |
Immunomedics, Inc. |
Immunotherapy of B-cell malignancies using anti-CD22 antibodies
|
|
US6372205B1
(en)
|
1997-06-11 |
2002-04-16 |
The School Of Pharmacy, University Of London |
Pharmaceutical compositions containing antibody-enzyme conjugates in combination with prodrugs
|
|
IT1293511B1
(it)
|
1997-07-30 |
1999-03-01 |
Gentili Ist Spa |
Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati
|
|
US6703488B1
(en)
|
1998-01-15 |
2004-03-09 |
Center For Molecular Medicine And Immunology |
Antibody/receptor targeting moiety for enhanced delivery of armed ligand
|
|
JP2002509158A
(ja)
|
1998-01-15 |
2002-03-26 |
センター・フォー・モレキュラー・メディシン・アンド・イムノロジー |
アーム付きリガンドの送達向上のための抗体と受容体ターゲティング部分
|
|
US6855804B2
(en)
|
1998-03-23 |
2005-02-15 |
Board Of Regents, The University Of Texas System |
Covalently reactive transition state analogs and methods of use thereof
|
|
US6235714B1
(en)
|
1998-03-23 |
2001-05-22 |
Sudhir Paul |
Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses
|
|
US7138103B2
(en)
|
1998-06-22 |
2006-11-21 |
Immunomedics, Inc. |
Use of bi-specific antibodies for pre-targeting diagnosis and therapy
|
|
AU1203000A
(en)
|
1998-10-09 |
2000-05-01 |
President And Fellows Of Harvard College |
Targeted proteolysis by recruitment to ubiquitin protein ligases
|
|
EP1212366B1
(en)
|
1999-07-30 |
2007-09-12 |
Medarex, Inc. |
Therapeutic compounds comprised of anti-fc receptor binding agents
|
|
WO2001036005A2
(en)
|
1999-11-15 |
2001-05-25 |
University Of Southern California |
Targeted delivery of therapeutic and diagnostic moieties
|
|
DE10034607A1
(de)
|
2000-07-20 |
2002-02-07 |
Gundram Jung |
Multispezifisches Reagenz zur selektiven Stimulierung von Zelloberflächenrezeptoren
|
|
EP1322750A4
(en)
|
2000-09-08 |
2004-09-29 |
California Inst Of Techn |
PROTEOLYSIS TARGET DRUG TARGET MEDICINE
|
|
US7105348B2
(en)
|
2000-10-31 |
2006-09-12 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
US20070258987A1
(en)
|
2000-11-28 |
2007-11-08 |
Seattle Genetics, Inc. |
Recombinant Anti-Cd30 Antibodies and Uses Thereof
|
|
US7431923B2
(en)
|
2005-01-03 |
2008-10-07 |
Arius Research Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD63
|
|
US7534429B2
(en)
|
2000-11-29 |
2009-05-19 |
Hoffmann-La Roche Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD63
|
|
US7560424B2
(en)
|
2001-04-30 |
2009-07-14 |
Zystor Therapeutics, Inc. |
Targeted therapeutic proteins
|
|
ATE423571T1
(de)
|
2001-10-12 |
2009-03-15 |
Schering Corp |
Verwendung von bispezifischen antikörpern gegen einen aktivierenden rezeptor fcepsilonri und gegen einen inhibierenden rezeptor ox2ra (cd200ra) zur regulierung der immunantworten
|
|
WO2003059194A2
(en)
|
2001-12-21 |
2003-07-24 |
Alcon, Inc. |
Use of synthetic inorganic nanoparticles as carriers for ophthalmic and otic drugs
|
|
US7332585B2
(en)
|
2002-04-05 |
2008-02-19 |
The Regents Of The California University |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
|
US20050142141A1
(en)
|
2002-11-27 |
2005-06-30 |
Pardridge William M. |
Delivery of enzymes to the brain
|
|
EP1633865B1
(en)
|
2003-06-18 |
2011-09-28 |
Bayer Pharma Aktiengesellschaft |
New biological entities and the use thereof
|
|
AU2003271174A1
(en)
|
2003-10-10 |
2005-04-27 |
Chugai Seiyaku Kabushiki Kaisha |
Double specific antibodies substituting for functional protein
|
|
NZ547588A
(en)
|
2003-11-07 |
2009-05-31 |
Immunex Corp |
Antibodies that bind interleukin-4 receptor
|
|
US7371539B2
(en)
|
2003-12-03 |
2008-05-13 |
President And Fellows Of Harvard College |
Targeted polypeptide degradation
|
|
US7235641B2
(en)
|
2003-12-22 |
2007-06-26 |
Micromet Ag |
Bispecific antibodies
|
|
EP1718667B1
(en)
|
2004-02-23 |
2013-01-09 |
Genentech, Inc. |
Heterocyclic self-immolative linkers and conjugates
|
|
US8754031B2
(en)
*
|
2004-03-08 |
2014-06-17 |
Oncolix, Inc. |
Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway
|
|
TW200539855A
(en)
|
2004-03-15 |
2005-12-16 |
Wyeth Corp |
Calicheamicin conjugates
|
|
WO2006108052A2
(en)
|
2005-04-06 |
2006-10-12 |
Genzyme Corporation |
Peg and polysialic lysosomal enzyme conjugates via acid labile linkers for therapeutic targeting
|
|
US7592429B2
(en)
|
2005-05-03 |
2009-09-22 |
Ucb Sa |
Sclerostin-binding antibody
|
|
CN105709237A
(zh)
*
|
2005-12-16 |
2016-06-29 |
Ibc 医药公司 |
基于免疫球蛋白的多价生物活性装配体
|
|
US7750116B1
(en)
|
2006-02-18 |
2010-07-06 |
Seattle Genetics, Inc. |
Antibody drug conjugate metabolites
|
|
NZ587107A
(en)
|
2006-06-02 |
2012-05-25 |
Regeneron Pharma |
High affinity antibodies to human il-6 receptor
|
|
US20080089891A1
(en)
|
2006-07-26 |
2008-04-17 |
Arius Research, Inc. |
Cancerous disease modifying antibodies
|
|
WO2008014404A2
(en)
*
|
2006-07-26 |
2008-01-31 |
The University Of Chicago |
Receptor-mediated delivery : compositions and methods
|
|
JP5638804B2
(ja)
|
2006-08-04 |
2014-12-10 |
アストラゼネカ アクチボラグ |
ＥｒｂＢ２に対する抗体
|
|
EP3018144A1
(en)
*
|
2006-08-18 |
2016-05-11 |
XOMA Technology Ltd. |
Prlr-specific antibody and uses thereof
|
|
WO2008122039A2
(en)
|
2007-04-02 |
2008-10-09 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Selenocysteine mediated hybrid antibody molecules
|
|
ES2731432T3
(es)
|
2007-05-23 |
2019-11-15 |
Ventana Med Syst Inc |
Transportadores poliméricos para inmunohistoquímica e hibridación in situ
|
|
WO2008150485A2
(en)
|
2007-05-29 |
2008-12-11 |
Wyeth |
Erbb2 binding proteins and use thereof
|
|
WO2008151219A1
(en)
|
2007-06-04 |
2008-12-11 |
Regeneron Pharmaceuticals, Inc. |
Enhanced expression and stability regions
|
|
US20090155275A1
(en)
|
2007-07-31 |
2009-06-18 |
Medimmune, Llc |
Multispecific epitope binding proteins and uses thereof
|
|
EP2238162A1
(en)
|
2008-01-24 |
2010-10-13 |
The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services |
Induced internalization of surface receptors
|
|
ES2456296T3
(es)
|
2008-03-27 |
2014-04-21 |
Zymogenetics, Inc. |
Composiciones y procedimientos para inhibir PDGFR beta y VEGF-A
|
|
DK2282764T3
(da)
|
2008-04-22 |
2019-10-14 |
Vib Vzw |
Leverspecifikke nukleinsyreregulerende elementer samt fremgangsmåder og anvendelser heraf
|
|
RU2487877C2
(ru)
|
2008-04-30 |
2013-07-20 |
Иммьюноджен, Инк. |
Высокоэффективные конъюгаты и гидрофильные сшивающие агенты (линкеры)
|
|
WO2010010324A1
(en)
|
2008-07-21 |
2010-01-28 |
Polytherics Limited |
Novel reagents and method for conjugating biological molecules
|
|
PE20110926A1
(es)
|
2008-09-26 |
2011-12-29 |
Roche Glycart Ag |
Anticuerpos biespecificos anti-egfr/anti-igf-1r
|
|
JP5587975B2
(ja)
|
2009-04-07 |
2014-09-10 |
ロシュ グリクアート アクチェンゲゼルシャフト |
二重特異的抗−ＥｒｂＢ−３／抗−ｃ−Ｍｅｔ抗体
|
|
EP2241576A1
(en)
|
2009-04-17 |
2010-10-20 |
Trion Pharma Gmbh |
Use of trifunctional bispecific antibodies for the treatment of tumors associated with CD133+/EpCAM+ cancer stem cells
|
|
LT2975051T
(lt)
|
2009-06-26 |
2021-07-12 |
Regeneron Pharmaceuticals, Inc. |
Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu
|
|
WO2011018613A1
(en)
|
2009-08-10 |
2011-02-17 |
Ucl Business Plc |
Functionalisation of solid substrates
|
|
WO2011029823A1
(en)
|
2009-09-09 |
2011-03-17 |
Novartis Ag |
Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
|
|
EP2332995A1
(en)
|
2009-12-10 |
2011-06-15 |
Bayer Schering Pharma Aktiengesellschaft |
Neutralizing prolactin receptor antibodies and their therapeutic use
|
|
HRP20151188T4
(hr)
|
2010-02-08 |
2021-10-01 |
Regeneron Pharmaceuticals, Inc. |
Miš sa zajedničkim lakim lancem
|
|
WO2011130598A1
(en)
|
2010-04-15 |
2011-10-20 |
Spirogen Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
US9453241B2
(en)
|
2010-05-04 |
2016-09-27 |
Wayne State University |
AAV-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells
|
|
CA3051311A1
(en)
|
2010-05-27 |
2011-12-01 |
Genmab A/S |
Monoclonal antibodies against her2
|
|
WO2012005982A2
(en)
|
2010-07-06 |
2012-01-12 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Reporter for rna polymerase ii termination
|
|
WO2012136519A1
(en)
|
2011-04-06 |
2012-10-11 |
Bayer Pharma Aktiengesellschaft |
Use of neutralizing prolactin receptor antibodies for the treatment and prevention of antiestrogen-resistant breast cancer
|
|
WO2012143523A1
(en)
|
2011-04-20 |
2012-10-26 |
Genmab A/S |
Bispecifc antibodies against her2
|
|
AU2012245116A1
(en)
|
2011-04-20 |
2013-11-07 |
Genmab A/S |
Bispecific antibodies against HER2 and CD3
|
|
JP2014514313A
(ja)
|
2011-04-20 |
2014-06-19 |
ロシュ グリクアート アクチェンゲゼルシャフト |
血液脳関門のｐＨ依存性通過のための方法及び構築物
|
|
EP2714685B1
(en)
|
2011-05-27 |
2016-10-19 |
Ambrx, Inc. |
Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
|
|
EP2530089A1
(en)
|
2011-06-03 |
2012-12-05 |
Bayer Pharma Aktiengesellschaft |
Neutralising prolactin receptor antibody Mat3 and its therapeutical use
|
|
US8815226B2
(en)
|
2011-06-10 |
2014-08-26 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
|
US9526798B2
(en)
|
2011-10-14 |
2016-12-27 |
Seattle Genetics, Inc. |
Pyrrolobenzodiazepines and targeted conjugates
|
|
MX358757B
(es)
|
2011-10-14 |
2018-09-03 |
Seattle Genetics Inc |
Pirrolobenzodiazepinas y conjugados dirigidos.
|
|
SG11201401021TA
(en)
|
2011-10-14 |
2014-08-28 |
Spirogen Sarl |
Pyrrolobenzodiazepines
|
|
US9102704B2
(en)
|
2011-10-14 |
2015-08-11 |
Spirogen Sarl |
Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines
|
|
WO2013068874A1
(en)
|
2011-11-11 |
2013-05-16 |
Pfizer Inc. |
Antibody-drug conjugates
|
|
AU2012348017A1
(en)
|
2011-12-05 |
2014-07-03 |
Igenica Biotherapeutics, Inc. |
Antibody-drug conjugates and related compounds, compositions, and methods
|
|
NZ631565A
(en)
|
2012-03-14 |
2016-07-29 |
Regeneron Pharma |
Multispecific antigen-binding molecules and uses thereof
|
|
CN104520327B
(zh)
|
2012-05-10 |
2019-01-18 |
酵活有限公司 |
单臂单价抗体构建体及其用途
|
|
US8883979B2
(en)
|
2012-08-31 |
2014-11-11 |
Bayer Healthcare Llc |
Anti-prolactin receptor antibody formulations
|
|
ES2659270T5
(en)
|
2012-10-23 |
2026-02-11 |
Synaffix Bv |
Modified antibody, antibody-conjugate and process for the preparation thereof
|
|
LT3115372T
(lt)
|
2012-11-27 |
2019-06-25 |
Biomarin Pharmaceutical Inc. |
Tiksliniai terapiniai lizosominio fermento sulieti baltymai ir jų panaudojimas
|
|
TWI682941B
(zh)
|
2013-02-01 |
2020-01-21 |
美商再生元醫藥公司 |
含嵌合恆定區之抗體
|
|
WO2014130723A1
(en)
|
2013-02-20 |
2014-08-28 |
Valerion Therapeutics, Llc |
Methods and compositions for treatment of pompe disease
|
|
JP2016515515A
(ja)
|
2013-03-15 |
2016-05-30 |
バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ |
抗プロラクチン受容体抗体製剤
|
|
EP3964237B1
(en)
|
2013-03-15 |
2026-02-18 |
Regeneron Pharmaceuticals, Inc. |
Biologically active molecules, conjugates thereof, and therapeutic uses
|
|
AU2014262566A1
(en)
*
|
2013-05-08 |
2015-11-12 |
Zymeworks Inc. |
Bispecific HER2 and HER3 antigen binding constructs
|
|
EA038367B1
(ru)
|
2013-05-20 |
2021-08-16 |
Дженентек, Инк. |
АНТИТЕЛА ПРОТИВ РЕЦЕПТОРА ТРАНСФЕРРИНА (TfR) И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ
|
|
CN104211814A
(zh)
|
2013-05-29 |
2014-12-17 |
三星电子株式会社 |
用于消耗靶膜蛋白的组合物
|
|
US9545451B2
(en)
|
2013-08-21 |
2017-01-17 |
Regeneron Pharmaceuticals, Inc. |
Anti-PRLR antibodies and methods for killing PRLR-expressing cells
|
|
TWI641620B
(zh)
|
2013-08-21 |
2018-11-21 |
再生元醫藥公司 |
抗－ｐｒｌｒ抗體及其用途
|
|
KR102252925B1
(ko)
|
2013-08-26 |
2021-05-18 |
리제너론 파마슈티칼스 인코포레이티드 |
마크롤라이드 디아스테레오머를 포함하는 약제학적 조성물, 이의 합성 방법 및 치료학적 용도
|
|
EP3137488B1
(en)
|
2014-06-11 |
2019-01-02 |
Molecular Templates, Inc. |
Protease-cleavage resistant, shiga toxin a subunit effector polypeptides and cell-targeting molecules comprising the same
|
|
WO2016077840A2
(en)
|
2014-11-14 |
2016-05-19 |
Ossianix, Inc. |
TfR SELECTIVE BINDING COMPOUNDS AND RELATED METHODS
|
|
MA41022A
(fr)
|
2014-11-24 |
2017-10-03 |
Shire Human Genetic Therapies |
Ciblage lysosomial et utilisations correspondantes
|
|
KR20240142591A
(ko)
|
2015-03-27 |
2024-09-30 |
리제너론 파아마슈티컬스, 인크. |
메이탄시노이드 유도체, 이의 컨주게이트, 및 사용 방법
|
|
MY189159A
(en)
|
2015-07-06 |
2022-01-29 |
Regeneron Pharma |
Multispecific antigen-binding molecules and uses thereof
|
|
KR20250133801A
(ko)
|
2015-12-08 |
2025-09-08 |
리제너론 파마슈티칼스 인코포레이티드 |
효소 내재화 조성물 및 방법
|
|
MY198605A
(en)
|
2016-01-25 |
2023-09-08 |
Regeneron Pharma |
Maytansinoid derivatives conjugates thereof, and methods of use
|
|
AR107483A1
(es)
|
2016-01-29 |
2018-05-02 |
Hanmi Pharm Ind Co Ltd |
Conjugado de enzimas terapéuticas
|
|
JP7676100B2
(ja)
|
2016-02-05 |
2025-05-14 |
ジェンマブ アクティーゼルスカブ |
改善された内部移行特性を有する多重特異性抗原結合分子
|
|
IL261246B2
(en)
|
2016-02-24 |
2023-03-01 |
Biomarin Pharm Inc |
Therapeutic fusion proteins targeting lysosomal enzymes, their formulations and their uses
|
|
WO2017190079A1
(en)
|
2016-04-28 |
2017-11-02 |
Regeneron Pharmaceuticals, Inc. |
Methods of making multispecific antigen-binding molecules
|
|
ES3065816T3
(en)
|
2017-06-07 |
2026-05-08 |
Regeneron Pharma |
Compositions and methods for internalizing enzymes
|
|
CN112040985A
(zh)
|
2018-02-07 |
2020-12-04 |
瑞泽恩制药公司 |
用于递送治疗性蛋白质的方法和组合物
|